BIOPHYTIS SA-ADR (BPTS) Fundamental Analysis & Valuation

NASDAQ:BPTS • US09076G2030

Current stock price

8.22 USD
-1.48 (-15.28%)
At close:
7.92 USD
-0.3 (-3.65%)
After Hours:

This BPTS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BPTS Profitability Analysis

1.1 Basic Checks

  • In the past year BPTS has reported negative net income.
  • BPTS had a negative operating cash flow in the past year.
  • In the past 5 years BPTS always reported negative net income.
  • In the past 5 years BPTS always reported negative operating cash flow.
BPTS Yearly Net Income VS EBIT VS OCF VS FCFBPTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • BPTS has a Return On Assets of -134.02%. This is amonst the worse of the industry: BPTS underperforms 84.47% of its industry peers.
Industry RankSector Rank
ROA -134.02%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BPTS Yearly ROA, ROE, ROICBPTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K

1.3 Margins

  • BPTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BPTS Yearly Profit, Operating, Gross MarginsBPTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. BPTS Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for BPTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BPTS Yearly Shares OutstandingBPTS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
BPTS Yearly Total Debt VS Total AssetsBPTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

  • BPTS has an Altman-Z score of -2.85. This is a bad value and indicates that BPTS is not financially healthy and even has some risk of bankruptcy.
  • BPTS has a Altman-Z score (-2.85) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.85
ROIC/WACCN/A
WACCN/A
BPTS Yearly LT Debt VS Equity VS FCFBPTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.81 indicates that BPTS may have some problems paying its short term obligations.
  • BPTS has a worse Current ratio (0.81) than 91.64% of its industry peers.
  • BPTS has a Quick Ratio of 0.81. This is a bad value and indicates that BPTS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.81, BPTS is doing worse than 91.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.81
BPTS Yearly Current Assets VS Current LiabilitesBPTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. BPTS Growth Analysis

3.1 Past

  • BPTS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.64%, which is quite impressive.
EPS 1Y (TTM)63.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BPTS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-133.33%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BPTS Yearly Revenue VS EstimatesBPTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 10M 20M 30M 40M
BPTS Yearly EPS VS EstimatesBPTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. BPTS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BPTS. In the last year negative earnings were reported.
  • Also next year BPTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BPTS Price Earnings VS Forward Price EarningsBPTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPTS Per share dataBPTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BPTS Dividend Analysis

5.1 Amount

  • BPTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BPTS Fundamentals: All Metrics, Ratios and Statistics

BIOPHYTIS SA-ADR

NASDAQ:BPTS (4/25/2024, 8:00:01 PM)

After market: 7.92 -0.3 (-3.65%)

8.22

-1.48 (-15.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15
Earnings (Next)09-25
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap94.20M
Revenue(TTM)N/A
Net Income(TTM)-19.58M
Analysts37.5
Price Target0.38 (-95.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-21.7%
PT rev (3m)-39.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-217.58%
EPS NY rev (3m)-108.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-17.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.8
EYN/A
EPS(NY)-3.52
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS0
BVpS-0.31
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -134.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.81
Altman-Z -2.85
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)55.71%
Cap/Depr(5y)70.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-133.33%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.85%
EBIT Next 3Y15.87%
EBIT Next 5YN/A
FCF growth 1Y18.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.89%
OCF growth 3YN/A
OCF growth 5YN/A

BIOPHYTIS SA-ADR / BPTS Fundamental Analysis FAQ

What is the fundamental rating for BPTS stock?

ChartMill assigns a fundamental rating of 0 / 10 to BPTS.


Can you provide the valuation status for BIOPHYTIS SA-ADR?

ChartMill assigns a valuation rating of 0 / 10 to BIOPHYTIS SA-ADR (BPTS). This can be considered as Overvalued.


Can you provide the profitability details for BIOPHYTIS SA-ADR?

BIOPHYTIS SA-ADR (BPTS) has a profitability rating of 0 / 10.


Can you provide the financial health for BPTS stock?

The financial health rating of BIOPHYTIS SA-ADR (BPTS) is 1 / 10.